Vestmark Advisory Solutions Inc. Sells 4,424 Shares of Smith & Nephew SNATS, Inc. $SNN

Vestmark Advisory Solutions Inc. reduced its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 29.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 10,842 shares of the medical equipment provider’s stock after selling 4,424 shares during the quarter. Vestmark Advisory Solutions Inc.’s holdings in Smith & Nephew SNATS were worth $332,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the stock. Ashton Thomas Securities LLC grew its stake in shares of Smith & Nephew SNATS by 0.9% in the 2nd quarter. Ashton Thomas Securities LLC now owns 55,911 shares of the medical equipment provider’s stock worth $1,713,000 after acquiring an additional 509 shares in the last quarter. Geneos Wealth Management Inc. lifted its position in shares of Smith & Nephew SNATS by 15.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,149 shares of the medical equipment provider’s stock valued at $118,000 after purchasing an additional 541 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its holdings in Smith & Nephew SNATS by 4.8% during the second quarter. Allspring Global Investments Holdings LLC now owns 12,462 shares of the medical equipment provider’s stock worth $381,000 after purchasing an additional 570 shares during the last quarter. Park Avenue Securities LLC grew its position in Smith & Nephew SNATS by 6.3% in the 2nd quarter. Park Avenue Securities LLC now owns 9,789 shares of the medical equipment provider’s stock worth $300,000 after purchasing an additional 583 shares in the last quarter. Finally, Gallacher Capital Management LLC grew its position in Smith & Nephew SNATS by 6.4% in the 2nd quarter. Gallacher Capital Management LLC now owns 10,622 shares of the medical equipment provider’s stock worth $325,000 after purchasing an additional 639 shares in the last quarter. 25.64% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on SNN. Sanford C. Bernstein set a $37.50 target price on Smith & Nephew SNATS and gave the stock a “market perform” rating in a research note on Tuesday, October 14th. Wall Street Zen lowered Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Friday, October 3rd. Canaccord Genuity Group cut their price objective on Smith & Nephew SNATS from $36.00 to $34.00 and set a “hold” rating on the stock in a research report on Tuesday. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada reissued an “outperform” rating on shares of Smith & Nephew SNATS in a report on Monday, October 20th. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $35.75.

Smith & Nephew SNATS Price Performance

NYSE SNN opened at $33.35 on Thursday. The company’s 50 day simple moving average is $36.23 and its two-hundred day simple moving average is $32.98. The company has a current ratio of 3.00, a quick ratio of 1.40 and a debt-to-equity ratio of 0.60. Smith & Nephew SNATS, Inc. has a 1 year low of $23.69 and a 1 year high of $38.79.

Smith & Nephew SNATS Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.